FMP

FMP

Enter

OSE.PA - OSE Immunotherapeuti...

Financial Summary of OSE Immunotherapeutics SA(OSE.PA), OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and re

photo-url-https://financialmodelingprep.com/image-stock/OSE.PA.png

OSE Immunotherapeutics SA

OSE.PA

EURONEXT

OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.

5.94 EUR

-0.37 (-6.23%)

About

ceo

Dr. Nicolas Poirier Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.ose-immuno.com

exchange

EURONEXT

Description

OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-12...

CIK

N/A

ISIN

FR0012127173

CUSIP

F6913C100

Address

22, boulevard Benoni Goullin

Phone

33 2 28 29 10 10

Country

FR

Employee

55

IPO Date

Mar 30, 2015

Summary

CIK

-

Exchange

EURONEXT

Industry

Biotechnology

Sector

Healthcare

CUSIP

F6913C100

ISIN

FR0012127173

Country

FR

Price

5.94

Beta

0.78

Volume Avg.

197.51k

Market Cap

129.21M

Shares

-

52-Week

2.705-8.63

DCF

-1.93

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-5.03

P/B

-

Website

https://www.ose-immuno.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest OSE.PA News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep